Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 9/20 | 0.46 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.46 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.38 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14770380 | 0.81 | LPAR3 (0.41) | LPAR3LPAR2LPAR1PLA2G2ABLM | |
| SCHEMBL14774045 | 0.76 | LPAR3 (0.45) | LPAR3LPAR2LPAR1PLA2G2ABLM | |
| SCHEMBL14740734 | 0.76 | LPAR3 (0.50) | LPAR3LPAR2LPAR1PLA2G2ABLM | |
| SCHEMBL14760633 | 0.71 | LPAR3 (0.47) | LPAR3LPAR2LPAR1PLA2G2ABLM | |
| SCHEMBL7153050 | 0.69 | LPAR3 (0.49) | LPAR3LPAR2LPAR1LPAR5P2RY10 | |
| SCHEMBL14747177 | 0.69 | LPAR3 (0.49) | LPAR3LPAR2LPAR1PLA2G2ABLM | |
| SCHEMBL7148541 | 0.69 | LPAR3 (0.49) | LPAR3LPAR2LPAR1LPAR5P2RY10 | |
| Hexadecyl Dihydrogen Phosphate SCHEMBL2809430 | 0.68 | LPAR3 (0.88) | LPAR3LPAR2LPAR1LPAR5 | |
| Phosphoric Acid Monotetradecyl Ester SCHEMBL28595278 | 0.68 | LPAR3 (0.88) | LPAR3LPAR2LPAR1LPAR5 | |
| SCHEMBL9189066 | 0.68 | LPAR3 (0.55) | LPAR3LPAR2LPAR1LPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150030541-A1 | NANOPARTICLE PEG MODIFICATION WITH H-PHOSPHONATES | MNK 2011 LLC (F/K/A MALLINCKRODT INC.) | 2015-01-29 | — | — | US | disclosed |
| US-20150030541-A1 | NANOPARTICLE PEG MODIFICATION WITH H-PHOSPHONATES | MNK 2011 LLC (F/K/A MALLINCKRODT INC.) | 2015-01-29 | — | — | US | disclosed |
| US-8889657-B2 | Nanoparticle PEG modification with H-phosphonates | MALLINCKRODT LLC (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889657-B2 | Nanoparticle PEG modification with H-phosphonates | MALLINCKRODT LLC (US) | 2014-11-18 | — | — | US | disclosed |
| US-20130066086-A1 | NANOPARTICLE PEG MODIFICATION WITH H-PHOSPHONATES | MALLINCKRODT LLC (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130066086-A1 | NANOPARTICLE PEG MODIFICATION WITH H-PHOSPHONATES | MALLINCKRODT LLC (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150030541-A1 | NANOPARTICLE PEG MODIFICATION WITH H-PHOSPHONATES | PHOSPHO1, PHPT1, HPSE | LPAR3 679/4885LPAR2 1113/4885LPAR1 773/4885 |
| US-20130066086-A1 | NANOPARTICLE PEG MODIFICATION WITH H-PHOSPHONATES | PHOSPHO1, PHPT1, HPSE | LPAR3 679/4885LPAR2 1113/4885LPAR1 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.